SLC5A2 and diabetes mellitus: Considering the discrepancies in efficacy between SGLT-2 inhibitors and GLP-1 agonists caused by mechanistic differences [34,35] or GLP-1 agonist type [9], in practice, SGLT-2 inhibitors and GLP-1 agonists should be cautiously applied to reduce MBG levels during the treatment of diabetes.